Posted by Kate Murphy on October 3rd, 2011
Good news for stage II colon cancer patients on Medicare. Oncotype DX® colon test is now covered.
Palmetto GBA, the designated national contractor for Oncotype DX Colon Cancer Assay, has determined that the test
Meets criteria for analytical and clinical validity and clinical utility as a reasonable and necessary Medicare benefit. Effective September 18, 2011, Palmetto GBA will reimburse Oncotype DX® Colon Cancer Assay services for patients diagnosed with Stage II colon cancer.
The Oncotype DX Colon Cancer Assay indicates how likely it is that stage II colon cancer will return (recur). It tests tumor tissue for twelve genes to develop a recurrence score that patients and their doctors can use in combination with other clinical information to make decisions about having chemotherapy after surgery.
The test does not predict whether or not chemotherapy will reduce risk of recurrence, but it does indicate risk for recurrence. Read the rest of this entry »